# Partners Investment

> Partners Investment is a VC fund backing Biotechnology and Health Care. See 130 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Seoul, South Korea
- Total investments: 130
- Last investment: Jun 2026
- Lead investor: 12%
- Last fund: Jan 2023
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/partners-venture-capital/about/
- Website: http://www.partnersi.co.kr/eng/
- Facebook: https://www.facebook.com/partnerinvestment

Partners Investment is a VC fund in Seoul focused on Biotechnology and Health Care. As a responsible and long-term partner, they aim to make various constructive contributions to portfolio companies.

## Contacts

5 contacts available for Partners Investment. Shizune tracks 2 team members at Partners Investment. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/partners-investment?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $2.5M–$30M |
| Series B | $5.5M–$98M |
| Series C | $7.4M–$87M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 30 | 23% |
| Health Care | 19 | 15% |
| Software | 13 | 10% |
| Pharmaceutical | 13 | 10% |
| Artificial Intelligence | 13 | 10% |

117 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 43 | 33% |
| Series B | 43 | 33% |
| Series C | 16 | 12% |
| Seed | 7 | 5% |
| Funding Round | 7 | 5% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| South Korea | 73 | 56% |
| United States | 16 | 12% |
| Japan | 1 | 1% |
| Vietnam | 1 | 1% |
| Singapore | 1 | 1% |

8 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Jaewan Kim | Founder and CEO | 0 | https://shizune.co/investors/profile/jaewan-kim-f102 |
| Yong Ha Kim | Managing Director | 2 | https://shizune.co/investors/profile/yong-ha-kim |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Solivis | Solivis is the manufacturer of solid-state batteries designed for next-generation battery packs. The company's product is used as a secondary battery for electric vehicles and has developed a wet synthesis method that can mass-produce a sulfide-based solid electrolyte with homogeneous high ionic conductivity, enabling clients to significantlyimprove productivity by reducing process costs and shortening the synthesis time. | $13.7M | Series C | Jun 04, 2026 |  |
| XCENA | XCENA is a semiconductor company that develops data-centric computing systems designed for AI and large-scale data processing environments. The company builds computational memory technology that combines high-capacity pooled DDR5 memory with near-data processing capabilities, allowing computation to occur closer to where data is stored. Its coreplatform is based on the Compute Express Link (CXL) standard, which enables memory expansion beyond traditional CPU limitations while improving data movement efficiency and reducing latency in data center workloads. XCENA’s architecture is designed to support applications such as artificial intelligence workloads, vector databases, and large-scale analytics by addressing memory bandwidth and capacity constraints. The company provides a hardware-software ecosystem that includes computational memory systems and a full-stack software development kit. This SDK offers APIs, runtime tools, and drivers that allow applications to use computational memory without major changes to existing software architectures while also supporting low-level control for performance optimization.XCENA’s flagship product line includes MX1, a CXL-based computational memory solution that integrates near-data processing engines with memory infrastructure to support AI inference and data-intensive workloads. The platform is designed to improve throughput and scalability in environments where traditional memory architectures become a bottleneck. The company operates in the broader field of AI infrastructure and memory innovation, working with customers such as hyperscalers, telecom providers, and research institutions that manage large-scale computing workloads. Its solutions are intended to improve efficiency in systems handling AI, big data processing, and scientific computing. | $135M | Series B | May 29, 2026 |  |
| Cenyx Biotech | Cenyx Biotech develops diagnostic and therapeutic nano-compounds formed based on nanozymes and nanoparticles. | $8.2M | Series B | Mar 31, 2026 |  |
| Mustbio | MustBio is a biotechnology company that leverages multi-antibody technology to develop therapeutics primarily in the field of immuno-oncology. The company was founded in 2021 and is based in Seoul, South Korea. | $23.3M | Series C | Mar 13, 2026 |  |
| BOS Semiconductors | BOS Semiconductors is a fabless semiconductor firm specializing in automotive-grade System-on-Chip (SoC) solutions and high-performance computing platforms. Its technologies support advanced driver assistance, autonomous driving, and centralized in-vehicle computing systems. | $60.3M | Series A | Feb 23, 2026 |  |
| ENCell | ENCell is a biotech company that develops and manufactures biopharmaceuticals. | $15.3M | Post-IPO Debt | Dec 04, 2025 |  |
| Sionic AI | Sionic AI is an information technology company that offers customized artificial intelligence platform services for business enterprises. It allows companies to design, manage, and utilize tailored AI services for business development and management. | $17M | Series A | Dec 01, 2025 |  |
| IMBiologics | IMBiologics is a biotechnology company that develops antibody-based drug candidates for diseases such as cancer and immune-related conditions. It conducts research and development using its own platforms to discover new therapeutic molecules. | $29.5M | Series C | Oct 14, 2025 |  |
| Nobo Medicine | Nobo Medicine is a clinical-stage biotech company focused on developing precision therapies for blood cancers and immune-related aging diseases. It uses biomarker-driven drug discovery and translational research to identify targeted treatments, aiming to improve outcomes in oncology and age-associated immune dysfunction through innovative,data-driven biomedical approaches. | $19.8M | Series C | Jul 28, 2025 |  |
| ASWEMAKE | ASWEMAKE is a provider of digital transformation management solutions, dedicated to creating a customer experience that makes purchasing daily necessities online as satisfying as buying them in person. By focusing on developing online sales infrastructure within competitive nationwide food ingredient markets and collaborating with local offlinepartners, the company aims to achieve 'Today's Shopping,' where orders made today are delivered the same day throughout the country, leveraging logistics and distribution services. It operates 'Q Market,' an application for same-day delivery from local grocery stores. Q Market serves as an O2O service that links consumers residing within a 3km radius of medium-to-large offline supermarkets, using city center supermarkets as delivery hubs to ensure that orders reach customers' doorsteps on the same day. The company is committed to offering consumers a fresher 'Convenience Premium' (Convenience + Premium) by setting itself apart through the use of logistics warehouses associated with supermarkets, ensuring that the products customers require are delivered as quickly as possible. | $7.4M | Series C | Jun 05, 2025 |  |

10 of 130 investments shown.

## Co-investors
- [Mirae Asset Venture Investment](https://shizune.co/investors/profile/mirae-asset-venture-investment) — VC Fund, 15 deals together
- [Korea Investment Partners](https://shizune.co/investors/profile/korea-investment-partners) — VC Fund, 14 deals together
- [Korea Development Bank](https://shizune.co/investors/profile/korean-development-bank) — VC Fund, 12 deals together
- [Atinum Partners](https://shizune.co/investors/profile/atinum-partners) — VC Fund, 9 deals together
- [IBK Capital](https://shizune.co/investors/profile/ibk-capital-951b) — VC Fund, 9 deals together
- [KB Investment](https://shizune.co/investors/profile/kbinvest) — VC Fund, 9 deals together

## Similar investors

### Similar industry
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Strong Ventures](https://shizune.co/investors/profile/strong-ventures) — VC Fund
- [Korea Credit Guarantee Fund](https://shizune.co/investors/profile/korea-credit-guarantee-fund) — VC Fund
- [Kakao Ventures](https://shizune.co/investors/profile/kakao-ventures) — VC Fund

## Featured in investor lists
- [All Investors in South Korea](https://shizune.co/investors/investors-south-korea)
- [All VC Funds in South Korea](https://shizune.co/investors/vc-funds-south-korea)
- [SaaS Investors in South Korea](https://shizune.co/investors/saas-investors-south-korea)
- [SaaS VC Funds in South Korea](https://shizune.co/investors/saas-vc-funds-south-korea)
- [Health Care Investors in South Korea](https://shizune.co/investors/health-care-investors-south-korea)
- [Health Care VC Funds in South Korea](https://shizune.co/investors/health-care-vc-funds-south-korea)

## FAQ

### What does Partners Investment invest in?

Partners Investment invests primarily in Biotechnology, Health Care and Software startups, most often at Series A and Series B stage. Most of the 130 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Partners Investment's check size?

Partners Investment typically joins rounds of $2.5M–$30M at Series A, $5.5M–$98M at Series B and $7.4M–$87M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Partners Investment participates in.

### How do I contact Partners Investment?

Public channels for Partners Investment include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Partners Investment?

The team at Partners Investment includes Jaewan Kim (Founder and CEO) and Yong Ha Kim (Managing Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co